Literature DB >> 8938271

Epitope selection and development of peptide based vaccines to treat cancer.

E Celis1, A Sette, H M Grey.   

Abstract

Cytotoxic T lymphocytes recognize peptides that associate with class I major histocompatibility complex molecules. Since cytotoxic T cells have the capacity to recognize and destroy tumor cells, identification of epitopes recognized by these cells in tumor-associated antigens would allow the production of compounds for the treatment of cancer. Here we review some of the approaches being explored to identify tumor-associated antigens and to develop peptide-based vaccines that induce cytotoxic T lymphocytes against specific tumors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8938271     DOI: 10.1016/1044-579x(95)90002-0

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  6 in total

1.  A subdominant CD8(+) cytotoxic T lymphocyte (CTL) epitope from the Plasmodium yoelii circumsporozoite protein induces CTLs that eliminate infected hepatocytes from culture.

Authors:  E D Franke; A Sette; J Sacci; S Southwood; G Corradin; S L Hoffman
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

2.  Effect of early immunization on the formation of the antitumor resistance system in mice.

Authors:  S D Kaz'min; I N Todor
Journal:  Dokl Biol Sci       Date:  2001 Jul-Aug

Review 3.  Prospects for the therapeutic use of anticancer vaccines.

Authors:  R S Chamberlain
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

Review 4.  The optimization of helper T lymphocyte (HTL) function in vaccine development.

Authors:  J Alexander; J Fikes; S Hoffman; E Franke; J Sacci; E Appella; F V Chisari; L G Guidotti; R W Chesnut; B Livingston; A Sette
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

Review 5.  The Interaction of Human Papillomavirus Infection and Prostaglandin E2 Signaling in Carcinogenesis: A Focus on Cervical Cancer Therapeutics.

Authors:  Janice García-Quiroz; Bismarck Vázquez-Almazán; Rocío García-Becerra; Lorenza Díaz; Euclides Avila
Journal:  Cells       Date:  2022-08-15       Impact factor: 7.666

6.  A novel prostate cancer immunotherapy using prostate-specific antigen peptides and Candida skin test reagent as an adjuvant.

Authors:  Al-Ola Abdallah; Hannah Coleman; Mohamed Kamel; Rodney Davis; Teri Landrum; Horace Spencer; Sam Mackintosh; Fade A Mahmoud; Natasa Milojkovic; Chester Wicker; Konstantinos Arnaoutakis; Mayumi Nakagawa
Journal:  SAGE Open Med       Date:  2018-09-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.